29 results
S-4/A
EX-10.23
KA
Kineta Inc
28 Oct 20
Registration of securities issued in business combination transactions (amended)
4:59pm
be taken to be an original; but such counterparts shall together constitute one and the same document.
22. Gender Neutral. Wherever used herein … , a pronoun in the masculine gender shall be considered as including the feminine gender unless the context clearly indicates otherwise.
IN WITNESS WHEREOF
425
EX-2.3
KA
Kineta Inc
24 Aug 20
Business combination disclosure
5:28pm
defined in the singular have the parallel meaning in the plural and vice versa; (d) words of one gender shall be construed to apply to each gender
8-K
EX-2.4
KA
Kineta Inc
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
defined in the singular have the parallel meaning in the plural and vice versa; (d) words of one gender shall be construed to apply to each gender
8-K
EX-2.3
KA
Kineta Inc
24 Aug 20
Yumanity Therapeutics and Proteostasis Therapeutics Announce
5:31pm
defined in the singular have the parallel meaning in the plural and vice versa; (d) words of one gender shall be construed to apply to each gender
8-K
EX-2.3
KA
Kineta Inc
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
” and its variants; (c) words defined in the singular have the parallel meaning in the plural and vice versa; (d) words of one gender shall be construed … to apply to each gender; and (e) the terms “Article,” “Section” and “Schedule” refer to the specified Article, Section or Schedule
S-4
EX-2.4
5bu45t
23 Sep 20
Registration of securities issued in business combination transactions
4:50pm
425
EX-2.4
yqgx9p3u
24 Aug 20
Business combination disclosure
5:28pm
8-K
EX-2.4
xbvw0egmh
24 Aug 20
Yumanity Therapeutics and Proteostasis Therapeutics Announce
5:31pm
S-4/A
EX-10.21
4f6 g68bjrjrs
28 Oct 20
Registration of securities issued in business combination transactions (amended)
4:59pm
8-K
EX-99.2
43l0spc
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
sv7 lg2ets3w
5 Jan 24
Regulation FD Disclosure
4:30pm
8-K
EX-99.2
dw4jb0ab0 gbe28pd
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
EX-10.1
tux1ind fhelzbx9pa
30 Dec 20
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
4:44pm
S-4/A
EX-10.17
j9b0yozynv177dpv
28 Oct 20
Registration of securities issued in business combination transactions (amended)
4:59pm
425
EX-2.2
223xi ztol
24 Aug 20
Business combination disclosure
5:28pm
8-K
EX-2.2
mmwd3aweop9ygqytcuoj
24 Aug 20
Yumanity Therapeutics and Proteostasis Therapeutics Announce
5:31pm
8-K
EX-1.1
7io6cj4n k1zm
9 May 19
Entry into a Material Definitive Agreement
8:07am